LABRHA participated in the last OARSI Congress which took place from the 31st of March to the 3rd of April 2016 in Amsterdam. The company presented the results of the double-blind, controlled, multicenter, randomized trial conducted on 226 patients and comparing the efficacy and tolerance of HAppyVisc® vs. Euflexxa®. Read more…
Steroids, lidocaine and ioxaglic acid modify the viscosity of hyaluronic acid: in vitro study and clinical implications. T. Conrozier; J. Patarin; P. Mathieu; M. Rinaudo. SpringerPlus . 2016 Feb 24;5:170; doi: 10.1186/s40064-016-1762-z. During viscosupplementation, it is usual to inject other drugs, without knowing whether this association may have a deleterious Read more…
TOL19-001 reduces inflammation and MMP expression in monolayer cultures of tendon cells by C. Baugé et al. BMC Complementary and Alternative Medicine 2015; 15:217; doi 10.1186/s12906-015-0748-7. Abstract Background Tendinopathies are tendon conditions associated with degeneration and disorganization of the matrix collagen fibers, tendon cells apoptosis and inflammation through up-regulation of Read more…
Viscosupplementation with HANOX-M-XL (HAppyCross®) is effective in moderate hip osteoarthritis but is not an alternative to hip joint surgery in patients with severe disease. Results of a “real life” clinical survey in 191 patients. T.Conrozier; M. Bossert; A. Walliser-Lohse; M. Sondag; JC Balblanc. Eur J Musculoskeletal Dis. 2015; 2:49-55. The Read more…
LABRHA actively participated in the 27th Annual Congress of the French Society of Rheumatology which took place in Paris from 7 to 9 December 2014. LABRHA was present with a booth in the exhibition area (F4-F5) where the company’s innovative portfolio and scientific projects were presented to the medical community. Read more…